




































The Pediatric Infectious Disease Journal • Volume XX, Number XX, XXX XXX www.pidj.com | 1
ISSN: 0891-3668/21/XXXX-0000
DOI: 10.1097/INF.0000000000003402
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This 
is an open access article distributed under the Creative Commons Attribu-
tion License 4.0 (CCBY), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
Antimicrobial Reports
Accepted for publication September 27, 2021
From the *Medical Research Council Centre for Medical Mycology, University 
of Exeter, United Kingdom; †St George’s University Hospitals NHS Foun-
dation Trust, London, United Kingdom; ‡Department of Paediatric Infec-
tious Diseases, Great Ormond Street Hospital for Children, London, United 
Kingdom; §The University of Queensland Centre for Clinical Research, 
Brisbane, Australia; ¶Department of Paediatric Oncology, Royal Marsden 
Hospital, Downs Road, Sutton, London, United Kingdom; ‖Department of 
Infectious Diseases and Immunology, Evelina Children Hospital, London, 
United Kingdom; **Oxford Vaccine Group, Department of Paediatrics, 
University of Oxford, Oxford, United Kingdom; ††Department of Paedi-
atric Immunology, Infectious Diseases and Allergy, Great North Children’s 
Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle 
upon Tyne, United Kingdom; ‡‡Institute of Cellular Medicine, Newcastle 
University, Newcastle upon Tyne, United Kingdom; §§Department of Paedi-
atric Infectious Diseases, Royal Manchester Childrens´ Hospital, Manches-
ter, United Kingdom; ¶¶Institute of Infection and Global Health, University 
of Liverpool, Liverpool, United Kingdom; ‖‖Department of Paediatric Infec-
tious Diseases, University Hospital Southampton NHS Foundation Trust, 
United Kingdom; ***Dept. of Paediatric Haematology and Oncology, Leeds 
General Infirmary, Leeds, United Kingdom; †††Department of Paediatric 
Infectious Diseases, Bristol Royal Hospital for Children, Bristol, United 
Kingdom; and ‡‡‡Paediatric Infectious Diseases, Imperial College Health-
care NHS Trust and Section of Paediatrics, Department of Infectious Dis-
eases, Imperial College, London, United Kingdom.
A.W. and L.F.-A. are supported by the MRC Centre for Medical Mycology (grant 
MR/N006364/2). The study was funded by a clinical fellowship award from 
Gilead Sciences.
The authors have no conflicts of interest to disclose.
Address for correspondence: Adilia Warris, MD, PhD, MRC Centre for Medical 
Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, 4EX 
4QD, Exeter, United Kingdom. Email: a.warris@exeter.ac.uk.
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Objective: The need for pediatric antifungal stewardship programs has 
been driven by an increasing consumption of antifungals for prophylactic 
and empirical use. Drivers and rational of antifungal prescribing need to be 
identified to optimize prescription behaviors.
Methods: A prospective modified weekly Point Prevalence Survey captur-
ing antifungal prescriptions for children (> 90 days to < 18 years of age) 
in 12 centers in England during 26 consecutive weeks was performed. 
Demographic, diagnostic and treatment information was collected for each 
patient. Data were entered into an online REDCap database.
Results: One thousand two hundred fifty-eight prescriptions were 
included for 656 pediatric patients, 44.9% were girls, with a median 
age of 6.4 years (interquartile range, 2.5–11.3). Most common underly-
ing condition was malignancy (55.5%). Four hundred nineteen (63.9%) 
received antifungals for prophylaxis, and 237 (36.1%) for treatment. 
Among patients receiving antifungal prophylaxis, 40.2% did not belong 
to a high-risk group. In those receiving antifungal treatment, 45.9%, 
29.4%, 5.1% and 19.6% had a diagnosis of suspected, possible, probable 
of proven invasive fungal disease (IFD), respectively. Proven IFD was 
diagnosed in 78 patients, 84.6% (n = 66) suffered from invasive can-
didiasis and 15.4% (n = 12) from an invasive mold infection. Liposomal 
amphotericin B was the most commonly prescribed antifungal for both 
prophylaxis (36.6%) and empiric and preemptive treatment (47.9%). 
Throughout the duration of the study, 72 (11.0%) patients received com-
bination antifungal therapy.
Conclusions: Antifungal use in pediatric patients is dominated by liposo-
mal amphotericin B and often without evidence for the presence of IFD. 
A significant proportion of prophylactic and empiric antifungal use was 
seen in pediatric patients not at high risk for IFD.
Key Words: antifungals, stewardship, prescriptions, children, amphotericin 
B, azoles
(Pediatr Infect Dis J 2021;XX:00–00)
The need for pediatric antifungal stewardship programs (pAFS) has been driven by an increasing consumption of 
antifungals for prophylactic and empirical use.1–3 Although partly 
explained by the challenges in the diagnosis of invasive fungal 
disease (IFD) and its associated high mortality, a poor under-
standing of who is at risk and timely access to diagnostic modali-
ties is likely to contribute to an overuse of antifungals. It is rec-
ognized that some cohorts of pediatric patients are at high risk 
of IFD,4 although new risk factors are being identified related 
to developments in immunosuppressive and immunomodula-
tory treatments.5,6 The current arsenal of fungal diagnostic tools 
has enabled a move away from an empiric to a preemptive man-
agement approach, which has been shown to be safe in reduc-
ing antifungal consumption.7 Overuse and inappropriate use 
of antifungals is expensive, drives antifungal resistance and is 
associated with increased adverse events.8 Antifungal steward-
ship (AFS) programs aim to reduce inappropriate antifungal use 
and to improve patient outcomes while reducing the evolution 
and spread of antifungal resistance. There is ample evidence 
from adult populations that AFS programs improve performance 
measures and decrease antifungal consumption.9–11 Currently, 
evidence on the value of pAFS programs is scarce.
The aims of the Paediatric Antifungal Stewardship: Opti-
mising Antifungal Prescription in Children study are to obtain an 
in-depth insight into antifungal prescribing behaviors in pediatric 




A prospective modified weekly point prevalence survey 
(PPS) capturing antifungal prescriptions for children (> 90 days–< 
18 years of age) in 12 hospitals in England during 26 consecutive 
weeks (June 2017 to January 2018) was performed. Each center 
collected the data on a specific day of each week.
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Study Definitions
A patient was defined at high risk for IFD if they suffered 
from any of the following: acute myeloid leukemia, relapsed acute 
myeloid leukemia, relapsed acute lymphoid leukemia, severe 
aplastic anemia, chronic granulomatous disease, severe combined 
immunodeficiency or had received a hematopoietic stem cell 
transplant (HSCT).12,13 IFD was classified as possible, probable 
and proven based on the European Organization for Research and 
Treatment of Cancer/Mycoses Study Group criteria.14 Antifun-
gal use included both prophylaxis and treatment. Treatment was 
defined as empiric (fever driven), preemptive (diagnostic driven) 
and targeted (evidence for IFD).15 The presence of the following 
risk factors were collected: central venous catheter, receipt of 
chemotherapy, corticosteroids > 0.3 mg/kg/d, other immunosup-
pressive therapy, persistent neutropenia (neutrophils < 0.5 × 109/L 
for ≥ 10 days), use of broad-spectrum antibiotic (eg, piperacillin-
tazobactam, meropenem, third- or fourth-generation cephalospor-
ins, amoxicillin/clavulanic acid) for ≥ 5 days, parenteral nutrition, 
abdominal surgery, graft-versus-host disease, known Candida spp. 
colonization within 2 weeks before inclusion. Changes in dose, 
dosing regimen or route of administration were counted as sepa-
rate prescriptions. The proportion of patients on antifungals per 
ward was calculated from the total of admissions at each individ-
ual ward during the successive PPS.
Data Collection
Demographic, diagnostic and treatment information were 
collected for each patient. Changes in the certainty of the IFD 
diagnosis and the antifungal prescriptions were captured while 
the patient was hospitalized. Data were collected via REDCap 
(Research Electronic Data Capture, Vanderbilt University, Nash-
ville, TN), a web-based application in which the investigators of 
the participating hospitals entered data online.
Statistical Analysis
The quantitative variables were expressed as mean ± SD 
when they followed a normal distribution, or as median and inter-
quartile range (IQR) when they had a non-normal distribution. 
Categorical variables were reported as frequency of distribution 
or rates and expressed as 2 × 2 tables. The distribution of fac-
tors by category of risk for IFD and the changes on treatment 
were analyzed using the χ2/Fisher tests or ANOVA test according 
to variable characteristics. Estimates were displayed using 95% 
confidence intervals. The statistical significance was defined as 
P < 0.05. All statistical analyses were performed using Stata SE 
software version 14.0.
RESULTS
Nine hundred and nineteen children > 90 days old were 
included. Patients admitted to neonatal wards (n = 6) and those 
being prescribed oral nystatin only (n = 257), were excluded from 
the analysis. The remaining 656 patients were included. Each 
weekly PPS involved a mean of 100 ± 10 patients (SD 10). Each 
individual patient was included in the study for a median of one 
PPS week (IQR, 1–3). 9.8% (64/656) of the children were included 
in the PPS for ≥ 8 weeks, and 4.4% (29/656) ≥ 12 weeks.
Demographics and Underlying Condition
Median age was 6.4 years (IQR, 2.5–11.3). The most com-
mon underlying condition was malignancy, n = 364 (55.5%). Sev-
enty patients (10.7%) were diagnosed with a primary immunode-
ficiency (PID) and 209 (31.9%) had other underlying conditions 
or were previously healthy children (Table 1). Of the 656 children, 
419 (63.9%) received antifungals for prophylaxis, and 237 (36.1%) 
for treatment at inclusion. Patients with PID and HSCT recipients 
received a higher proportion of antifungal prophylaxis compared 
with antifungal treatment (13.1% vs. 6.3% and 34.6% vs. 13.9%, 
respectively, P < 0.01) (Table 2).
Most children receiving antifungals for therapeutic pur-
poses had no diagnosis of IFD, 45.9% (95% CI, 41.5%–50.3%). 
Of those with a diagnosis of IFD, 29.4% (95% CI, 26.3%–32.5%) 
had a possible, 5.1% (95% CI, 3.4%–6.8%) probable and 19.6% 
(95% CI, 17.2%–21.9%) proven IFD. Among the children with a 
proven IFD for which microbiological data was provided (n = 78), 
invasive candidiasis was diagnosed in 66 (84.6%), invasive asper-
gillosis in 5 (6.4%) and other invasive mold infections in 7 (9.0%). 
Of the patients who were started on antifungal treatment at inclu-
sion (n = 237), only 25 (10.6%) had a change in the certainty of the 
IFD diagnosis within the successive weeks.
TABLE 1. Characteristics of the Study Population
Patients (n) 656  
Age (y) 6.4 y (IQR, 2.5–11.3)
Sex, female 293 (44.9%)  
Underlying conditions,* n (%)   
Malignancy 364 (55.5%)  
 ALL  85 (23.5%)
 Relapsed ALL  68 (18.8%)
 AML  60 (16.6%)
 Relapsed AML  16 (4.4%)
 Other leukemias  25 (6.9%)
 Non-Hodgkin lymphoma  22 (6.1%)
 Hodgkin lymphoma  4 (1.1%)
 Solid tumors  80 (20.2%)
 Not specified  4 (1.1%)
Underlying condition PID 70 (10.7%)  
 (S)CID  25 (35.7%)
 Chronic granulomatous disease  12 (17.2%)
 Chronic mucocutaneous candidiasis  1 (1.4%)
 Other types of PID  32 (45.7%)
Underlying condition “other” 207 (31.6%)  
 Hematologic disorder without bone  
 marrow suppression
 30 (14.6%)
 Congenital heart disease (surgical)  24 (11.7%)
 SOT  19 (9.2%)
 CF  17 (8.3%)
 Disorder with bone marrow suppression  14 (6.8%)
 Gastrointestinal disease  14 (6.8%)
 Surgical abnormality/condition  13 (6.3%)
 None  12 (5.8%)
 Post-HSCT  12 (5.8%)
 Other†  52 (25.1%)
Risk factors, n (%)   
 CVC 501 (76.4)  
 Chemotherapy 328 (50.0)  
 Broad-spectrum antibiotic (≥ 5 d) 267 (40.7)  
 Peritransplant (HSCT or SOT) 197 (30.0)  
 Prolonged neutropenia (≥ 10 d) 191 (29.1)  
 Immunosuppressive therapy  
 (nonchemotherapy)
174 (26.5)  
 Steroid treatment (dose >0.3 mg/kg/d) 107 (16.3)  
 Parenteral nutrition 89 (13.6)  
 Candida colonization 68 (10.4)  
 Abdominal surgery 52 (7.9)  
 GvHD 38 (5.8)  
*No underlying condition reported in 15 patients.
†Categories with < 10 patients in each group, including inborn errors of metabo-
lism; nonsurgical heart disease; chronic renal disease; chromosomal/single gene disor-
der; chronic neurologic condition; rheumatologic or inflammatory condition; neurosur-
gical abnormality; chronic respiratory disease; chronic endocrinologic disease.
(S)CID indicates severe combined immunodeficiency; ALL, acute lymphoblas-
tic leukemia; AML, acute myeloid leukemia; CF, cystic fibrosis; CVC, central venous 
catheter; GvHD, graft-versus-host disease; ICU, intensive care unit; SOT, solid organ 
transplant.
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Most patients receiving antifungals had at least one risk fac-
tor for IFD (n = 629, 95.9%). A single risk factor was reported in 
95 patients (14.5%), 2 in 136 (20.7%), and ≥ 3 in 398 (60.7%) 
(Table 1).
Among the patients receiving antifungal prophylaxis, 40.2% 
did not belong to a high-risk group, with 71.4% of the non-high-risk 
group having ≥ 2 risk factors. Among the non-high-risk patients 
receiving empiric treatment, 72.6% had ≥ 2 risk factors (Table 3).
Ward of Admission
The majority of the patients were admitted to hematol-
ogy-oncology wards (n = 313; 47.7%), followed by HSCT wards 
(n = 130, 19.8%) and pediatric intensive care unit (PICU; n = 88, 
13.4%). The proportion of admitted children receiving antifungals 
was highest on the HSCT wards: 59.8% (95% CI, 56.5%–63.2%), 
followed by hematology-oncology wards: 38.3% (95% CI, 36.3%–
40.3%), and PICU: 17.6% (95% CI, 15.5%–19.7%).
Antifungal Prescriptions
The total number of prescriptions was 1258. Most prescrip-
tions were for prophylaxis, 70.7% (95% CI, 62%–79.5%), with 
29.3% (95% CI, 20.5%–38%) for treatment. Among the differ-
ent types of treatment, 29.9% (95% CI, 21.3%–38.5%) were for 
empiric treatment; 57.4% (95% CI, 46.2%–68.5%) for preemptive 
treatment and 12.8% (95% CI, 8.2%–17.3%) for targeted treatment.
Liposomal amphotericin B (L-AmB) was the most com-
monly prescribed antifungal (n = 474, 37.7%), followed by mold-
active azoles (n = 459, 36.5%). Of the mold-active azoles, itracona-
zole was prescribed most commonly (n = 265, 49.2%) (Table 4).
The 2 most common agents prescribed for prophylaxis 
were L-AmB (n = 275 prescriptions, 36.6%) and itraconazole 
(n = 260 prescriptions, 34.6%). Most of the L-AmB prescriptions 
for prophylaxis were in patients with an underlying malignancy 
[170/275 (61.8%)]. Of all the patients who were on L-AmB proph-
ylaxis (n = 192) or itraconazole (n = 177), 66.1% (127/192) and 
74.6% (132/177), respectively, were at high risk for IFD. Prescrip-
tions for fluconazole prophylaxis (n = 81) were mainly observed in 
non-high-risk patients (64/81; 79.0%), including those with non-
high-risk malignancies (n = 23) and SOT recipients (n = 14).
L-AmB was the antifungal of choice for either empiric 
[89/189 (47.1%)] or preemptive treatment [84/172 (48.8%)]. Inter-
estingly, the second most commonly prescribed antifungal agent 
for empiric treatment was fluconazole (46/189, 24.3%) to predomi-
nantly non-high-risk patients (42/46, 91.3%).
When comparing the total prescriptions for prophylaxis and 
empiric treatment (Table 4) with those prescribed to patients with 
underlying malignancies and HSCT only (Table 5), differential pre-
scription behaviors were noted. The high-risk patients presented a 
higher proportion of itraconazole prophylaxis prescriptions com-
pared to the total cohort (41.6% vs. 34.6%); whereas the proportion 
of fluconazole prophylaxis was lower (1.1% vs. 11.3%). Analysis of 
the prescriptions for empiric treatment showed a higher proportion 
of high-risk patients received L-AmB compared with the whole 
cohort (56.8% vs. 47.1%). Fluconazole was rarely prescribed as 
empiric treatment to high-risk patients (4.9%).
Combination Therapy
At inclusion, 47 (7.2%) children received combination ther-
apy with 2, and one child with 3 antifungals. Throughout the dura-
tion of the study, a total of 72 (11.0%) patients received dual, and 2 
(0.3%) received triple antifungal therapy. Of those on combination 
therapy, 58 (78.4%) were patients at high risk for IFD. Combination 
therapy accounted for 108 prescriptions, of which 33 (30.9%) were 
prescriptions for proven or probable IFD, whereas 31 (29.0%) and 
44 (40.2%) were in patients with possible and no diagnosis of IFD.
Prescription Changes
During the successive PPS weeks, 509 changes were made to 
prescriptions affecting 259 (39.5%) patients. Of those, 311 (61.1%) 
changes were deescalation measures, either a switch from intrave-
nous to oral or from combination therapy to monotherapy. A total 
of 155 (30.4%) were related to a change from treatment to prophy-
laxis (stepping-down). The rational for those changes were either 
based on clinical judgment (75.6% in deescalation and 91.6% for 
TABLE 2. Rationale for Antifungal Prescription Grouped by Underlying Condition
Underlying condition,* N (%) Prophylaxis, n = 419 Treatment, n = 237 P value Total, n = 656
Malignancy 230 (54.8) 134 (56.5) 0.664 364 (55.5)
 Leukemia 173 (75.2) 80 (59.8)  253 (71.4)
 Lymphoma 15 (6.5) 11 (8.3)  26 (7.3)
 Solid organ tumor 38 (16.5) 42 (31.2)  80 (22.6)
 Other 4 (1.8) 1 (0.7)  5 (1.4)
HSCT recipients† 145 (34.7) 33 (13.9) <0.01 178 (27.1)
Primary Immunodeficiency 55 (13.2) 15 (6.3) <0.01 70 (10.7)
Others 126 (30.1) 81 (34.2) 0.286 207 (31.6)
*No underlying condition reported in 15 patients.
†Irrespective of underlying condition.
TABLE 3. Distribution of Number of Risk Factors by Rationale of Treatment: Prophylaxis 
and Empiric Treatment
Number of risk  
factors, n (%)
Prophylaxis (n = 418) Empiric treatment (n = 107)
High risk  
(n = 250, 59.8%)
Non-high risk  
(n = 168, 40.2%) P value
High risk  
(n = 34, 31.8%)
Non-high risk  
(n = 73, 68.2%) P value
None 5 (2) 16 (9.5) <0.01 0 (0) 0 (0) <0.01
1 22 (8.9) 32 (19.0) 1 (2.9) 20 (27.4)
2 40 (16) 54 (32.1) 1 (2.9) 19 (26)
≥ 3 183 (73.2) 66 (39.3) 32 (94.1) 34 (46.6)
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stepping-down). Figure 1 shows the differentiated rational for the 
prescription changes made.
DISCUSSION
The results of this PPS show that the majority of pediatric 
antifungal prescriptions are for patients without evidence of IFD and 
that L-AmB is the most commonly used antifungal for both prophy-
lactic and therapeutic purposes. A significant proportion of antifun-
gal consumption was observed in pediatric patients whose underlying 
condition is not recognized as rendering them at high risk for IFD.
The majority of the prescriptions (70%) were for antifun-
gal prophylaxis, which is a higher figure than previously reported 
in a comparable, but single PPS, showing 46% of the antifungal 
prescriptions to be for antifungal prophylaxis.1 This higher propor-
tion seems not to be due to a larger population of children being at 
risk, as in our study, 40% could not be categorized as being at high 
risk to develop IFD. The practice of defining categories of pediatric 
patients being at low, moderate and high risk for IFD has been used 
to establish management recommendations for children with hema-
tologic malignancies and those undergoing HSCT.12 For children 
with PID, defects in specific innate immune pathway (eg, STAT-3 
deficiency), severe impairment of neutrophil function (chronic 
granulomatous disease) or T-cell function (severe combined immu-
nodeficiency) are associated with a high risk of developing IFD.4,16 
For those high-risk pediatric patients, antifungal prophylaxis is 
recommended as antifungal prophylaxis has shown to decrease the 
incidence of IFD.12,13,17 Several studies have defined individual risk 
factors associated with the development of IFD. Prolonged neu-
tropenia, the use of high-dose steroids, the presence of graft-ver-
sus-host disease, delayed lymphocyte engraftment are risk factors 
associated with the development of IFD in patients with hemato-
oncological disorders and HSCT recipients.18,19 Central venous 
catheters, parenteral nutrition, the prolonged use of vancomycin 
or agents with activity against anaerobic organisms enhances spe-
cifically the risk of invasive candidiasis in the intensive care set-
ting, next to those admitted to hemato-oncology wards and HSCT 
units.19–21 Our results reflect this specified risk to a certain extent, as 
fluconazole was prescribed more commonly as a prophylactic agent 
outside the patient population being at high risk for IFD caused by 
both yeasts and molds. The combination of the underlying condi-
tion and the presence of risk factors are often taken into account 
when prescribing antifungal prophylaxis and empiric antifungal 
therapy. A number of predictive risk models for invasive candidi-
asis have been developed to guide antifungal therapy for children 
admitted to the PICU.22–24 Unfortunately, those models have either 
not been validated22,23 or failed to do so.25 Recently, a predictive 
risk model was described to estimate the 60-day probability of 
developing probable or proven invasive mold disease in hematol-
ogy patients.26 Potential use of such prediction models is to allow 
for targeted biomarker screening and fine-tuning of management 
strategies (eg, prophylaxis, empiric therapy) thereby optimizing 
antifungal prescribing. Our study showed that amongst the non-
high-risk population who were on either antifungal prophylaxis or 
TABLE 4. Rationale for Prescription of Specific Antifungal Agents
Agent, n (%) Prophylaxis (n = 752)
Treatment
Total (n = 1227)*Empiric (n = 189) Preemptive (n = 172) Targeted (n = 114)
L-AmB 275 (36.6) 89 (47.1) 84 (48.8) 19 (16.7) 467
Itraconazole 260 (34.6) 1 (0.5) 1 (0.6) 3 (2.6) 265
Voriconazole 48 (6.4) 18 (9.5) 30 (17.4) 14 (12.3) 110
Posaconazole 47 (6.2) 9 (4.8) 7 (4.1) 8 (7.0) 71
Isavuconazole 0 0 0 1 (0.9) 1
Fluconazole 85 (11.3) 46 (24.3) 13 (7.6) 49 (43.0) 193
Micafungin 26 (3.4) 11 (5.8) 28 (16.3) 3 (2.6) 68
Caspofungin 8 (1.1) 10 (5.3) 7 (4.1) 11 (9.6) 36
Anidulafungin 0 0 0 1 (0.9) 1
Flucytosine 0 0 0 5 (4.4) 5
Other AmB 3 (0.4) 5 (2.6) 2 (1.2) 0 10
*Total prescriptions 1258, from those, 1227 with full information on rational.
Other AmB: amphotericin B deoxycholate and lipids formulations of amphotericin B.
TABLE 5. Proportion of Prescriptions of the Different Agents as Prophylaxis or Empiric Treat-
ment in the Groups With Underlying Malignancies and HSCT Categorized by Risk
Antifungal agent
Prophylaxis Empiric treatment
High risk  
(n = 449)
Non-high risk +  
neutropenia (n = 54)
Solid tumors  
(n = 97)
High risk  
(n = 81)
Non-high risk +  
neutropenia (n = 33)
Solid tumors  
(n = 33)
L-AmB 175 (39.0%) 20 (37.0%) 42 (43.3%) 46 (56.8%) 17 (51.5%) 17 (51.5%)
Itraconazole 187 (41.6%) 12 (22.2%) 17 (17.5%) 1 (1.2%) 0 0
Voriconazole 26 (5.8%) 6 (11.1%) 15 (15.5%) 7 (8.6%) 3 (9.0%) 4 (12.2%)
Posaconazole 36 (8.0%) 3 (5.6%) 0 7 (8.6%) 1 (3.0%) 0
Fluconazole 5 (1.1%) 8 (14.8%) 15 (15.5%) 4 (4.9%) 8 (24.2%) 8 (24.2%)
Echinocandins 18 (4.0%) 5 (9.2%) 7 (7.2%) 12 (14.8%) 4 (12.1%) 3 (9.1%)
Other 2 (0.4%) 0 1 (1.0%) 4 (4.9%) 0 1 (3.0%)
High risk: post-HSCT patients, relapsed acute lymphoblastic leukemia, acute myeloid leukemia, relapsed acute myeloid leukemia, Hodgkin lym-
phoma. Non-high risk: acute lymphoblastic leukemia (regardless of chemotherapy protocol), other leukemias, non-Hodgkin lymphomas.
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received empirical treatment, less than half of the patients had three 
or more risk factors. Targeting the high number of antifungal pre-
scriptions in non-high-risk pediatric populations is needed and will 
be of value to improve the rational use of antifungals.
L-AmB was the most frequently prescribed antifungal for 
prophylaxis. This is surprising as it is not licensed for prophylaxis, 
efficacy data are not known, and no dosing recommendations for 
prophylactic use exists. Experiences with L-AmB prophylaxis 
are restricted to single-center reports.27,28 The compatibility with 
vincristine, fewer drug-drug interactions and lack of the need to 
perform therapeutic drug monitoring, are the most likely reasons 
to prescribe L-AmB instead of a mold-active azole. Some clinical 
management guidelines mention L-AmB as an alternative antifun-
gal prophylaxis for pediatric patients, although with a low evidence 
grading due to lack of data.12,13
The European Organization for Research and Treatment of 
Cancer/Mycoses Study Group Consensus Definitions provide a tool 
to make a diagnosis of IFD with a specified level of certainty.14 It has 
recently undergone a second revision and the revised version captures 
for the first time pediatric-specific signs and symptoms.14 It should be 
stressed, though, that these definitions are specifically intended for 
the purpose of facilitating epidemiologic and clinical research and 
do not aim to direct patient care. Our results might indirectly demon-
strate that the host factors summarized in the Consensus Definitions 
are being used in the decision to prescribe antifungal therapy.
L-AmB was shown to be the antifungal of choice in almost 
50% of patients for empirical and preemptive therapy. Both caspo-
fungin and L-AmB are recommended for empirical treatment in 
hemato-oncologic patients with febrile neutropenia.12,13,29 From an 
AFS perspective, it is critical to review empiric antifungal therapy 
at least weekly, as most patients on empiric therapy will not have an 
IFD. Preemptive antifungal therapy is a diagnostic-driven approach 
enabling a more targeted antifungal therapy. Our data does not 
reflect this differentiation in approach based on the specific antifun-
gal prescribed and may have several explanations. Current fungal 
biomarkers are only available for a restricted number of fungi (eg, 
Candida and Aspergillus species), abnormalities on CT-chest do not 
identify the causative fungus, and azole-resistant aspergillosis drives 
the use of L-AmB if cultures are negative and susceptibility testing 
is not performed. Fung et al7 published a meta-analysis comparing 
empirical and preemptive antifungal therapy in adult patients with 
high-risk febrile neutropenia and reported decreased antifungal use 
without increasing mortality and no major economic impact when 
the latter strategy was used. A Cochrane review published in 2015 
reported insufficient data to support a preemptive approach in chil-
dren,30 and this still remains an important research gap. In the mean-
time, 2 single-center studies have been published supporting the use 
of a preemptive approach in children with febrile neutropenia.31,32
The finding of a majority of the antifungal prescriptions for 
pediatric patients without evidence of IFD might indirectly reflect a 
limitation to access available fungal diagnostics tools. We have pre-
viously reported that the use of fungal diagnostic tools varied with 
a prolonged turn-around time being an important barrier for many 
centers.33 To improve antifungal prescribing in situations where IFD 
is clinically suspected, efforts should be focused on the access to 
timely fungal diagnostics. The current indirect fungal markers (eg, 
β-D-glucan, galactomannan, lateral flow assay) and polymerase 
chain reaction-based tests are of high value to exclude the presence 
of IFD and are able to guide decisions to rationalize antifungal use.34
It is worth to consider the limitations of our modified PPS. 
While changes in diagnosis of IFD and prescriptions were captured, 
qualitative information such as changes in the clinical condition 
of the patient and diagnostics results were not collected. Prescrip-
tion data was only collected when patients were admitted to the 
hospital, and therefore, information on the duration of antifungal 
prophylaxis or treatment is lacking. In addition, the impact of local 
guidelines was not assessed.
The Paediatric Antifungal Stewardship: Optimising Antifun-
gal Prescription in Children modified PPS has identified key areas 
to be addressed in a pAFS program to optimize antifungal prescrib-
ing. The unexplained high use of antifungal prophylaxis outside the 
defined high-risk populations, and a significant use of antifungals 
as treatment in patients with suspected IFD. It reflects the challenge 
of recognizing who is at high risk, the difficulties encountered in 
either ruling in or ruling out of the presence of IFD with the cur-
rent diagnostic tools, as well as timely access to fungal diagnostic 
tools. Further development and validation of predictive risk models 
in specific patient populations has the potential to more precisely 
define the patient at risk and to optimize antifungal use. Providing 
targeted educational programs and improving the access to fungal 
diagnostic and reporting of results are urgently needed. Establish-
ing pAFS teams within individual centers is most likely to be of 
FIGURE 1. Frequency of prescription changes along the successive PPS weeks by type of change and rational registered for 
this change. Numbers within brackets represent number of patients. TDM indicates therapeutic drug monitoring.
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important value to further improve rational antifungal prescription 
behavior as a recent single pediatric center study has shown.35
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